Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: Correlation with tumor grade

International Journal of Gynecological Cancer

Volumn 15, Issue 3, 2005, Pages 438-444

  Simaga S ^a   Osmak, M ^a   Babic D ^b   Sprem M ^b   Vukelic B ^a   Abramič, Marija ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Human ovary; Lactate dehydrogenase; Ovarian cancer

Indexed keywords

GLYCOLYTIC ENZYME; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CELL TYPE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; FEMALE; GLYCOLYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEASUREMENT; MUCINOUS CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CYTOSOL; EPITHELIUM; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY;

EID: 18944370951     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.14410.x     Document Type: Article

References (35)

1. Warburg O. Ist die aerobe Glykolyse spezifisch für die Tumoren? Biochem Z 1929;204:482-3.
2. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene: multiple genes for LDH isozymes provide a model of the evolution of gene structure, function, and regulation. Science 1975;189:102-14.
3. Kopperschläger G, Kirchberger J. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. J Chromatogr B 1996;684:25-49.
4. Cahn RD, Kaplan NO, Levine L, Zwilling E. Nature and development of lactic dehydrogenase. Science 1962;136:962-9.
5. Markert CL. Lactate dehydrogenase isozymes: dissociation and recombination of subunits. Science 1963;140:1329-30.
6. Langvad E, Pedersen SN. LDH-isoenzyme patterns in the nonmalignant and malignant uterine cervix. Cancer 1969;23:1171-5.
7. Virgolini L, Silvestri F, Fasola G et al. Serum isoenzymatic lactate dehydrogenase pattern in acute non-lymphocytic leukemia. Eur J Lab Med 1993;1:173-6.
8. Friedman M, White RG, Nissenbaum MM, Browde S. Serum lactic dehydrogenase - a possible tumor marker for an ovarian dysgerminoma: a literature review and report of a case. Obstet Gynecol Surv 1984;39:247-51.
9. Patel PS, Sharma VM, Raval GN et al. Serum lactate dehydrogenase levels in malignant germ cell tumors of ovary. Int J Gynecol Cancer 1996;6:328-32.
10. Huijgen HJ, Sanders GTB, Koster RW, Vreeken J, Bossuyt PMM. The clinical value of lactate dehydrogenase in serum: a quantitative review. Eur J Clin Chem Clin Biochem 1997;35:569-79.
11. Awais GM. Serum lactic dehydrogenase levels in the diagnosis and treatment of carcinoma of the ovary. Am J Obstet Gynecol 1973;116:1053-7.
12. Kikuchi Y, Kizawa I, Koyama E, Kato K. Significance of serum tumor markers in patients with carcinoma of the ovary. Obstet Gynecol 1984;63:561-6.
13. Schneider D, Halperin R, Langer R, Bukovsky I, Herman A. Peritoneal fluid lactate dehydrogenase in ovarian cancer. Gynecol Oncol 1997;66:399-404.
14. McGowan L, Davis RH, Bunnag B. The biochemical diagnosis of ovarian cancer. Am J Obstet Gynecol 1973;116:760-8.
15. Burrows S. Serum enzymes in the diagnosis of ovarian malignancy. Am J Obstet Gynecol 1980;137:140-1.
16. Knight JA, Wu JT, Miya T, Knight DP. Comparison of biochemical markers between benign and malignant ovarian cysts. Clin Physiol Biochem 1986;4:130-5.
17. Boran N, Kayikcioglu F, Yalvac S, Tulunay G, Ekinci U, Kose MF. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer. Gynecol Obstet Invest 2000;49:272-4.
18. Šimaga Š, Babič D, Osmak M et al. Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue. Eur J Cancer 1998;34:399-405.
19. Šprem M, Babič D, Abramič M et al. Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series. Croat Med J 2001;42:624-9.
20. Wróblewski F, LaDue JS. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955;90:210-3.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
22. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
23. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 2002;299:676-80.
24. Stubbs M, Bashford CL, Griffiths JR. Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med 2003;3:49-59.
25. Chow S-N, Lin J-K, Li SS-L, Chien C-H. Identification of LDH-ras p21 protein complex and expression of these genes in human ovarian cancer. Gynecol Oncol 1997;64:114-20.
26. Pioli PA, Hamilton BJ, Connolly JE, Brewer G, Rigby WFC. Lactate dehydrogenase is an AU-rich element-binding protein that directly interacts with AUF1. J Biol Chem 2002;277:35738-45.
27. Crawford RM, Budas GR, Jovanovic S et al. M-LDH serves as a sarcolemmal K-ATP channel subunit essential for cell protection against ischemia. EMBO J 2002;21:3936-48.
28. Yuce K, Baykal C, Gene C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynecol Oncol 2001;22:228-32.
29. Ross CD, Gomaa MA, Gillies E, Juengel R, Medina JE. Tumor grade, microvessel density, and activities of malate dehydrogenase, lactate dehydrogenase, and hexokinase in squamous cell carcinoma. Otolaryngol Head Neck Surg 2000;122:195-200.
30. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
31. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002;41:79-83.
32. Nakayama K, Kanzaki A, Hata K et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 2002;176:215-23.
33. Tanner B, Hengstler JG, Luch A et al. C-MYC mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time FIGO stage, and histologic grade and type. Int J Gynecol Pathol 1998;17:66-74.
34. Shim H, Dolde C, Lewis BC et al. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997;94:6658-63.
35. Jazaeri AA, Lu K, Schmandt R et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-9.